Poland· PL-100435166

Sorafenib Sandoz

A gefitinib product containing sorafenibum, registered in Poland by Sandoz GmbH. The same ATC class is registered in 2 of our 19 countries.

ATC L01XE02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSorafenib SandozATCL01XE02REGISTER NO.PL-100435166PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Gefitinib is registered in 2 of 19 countries.

Countries holding a registration under ATC L01XE02 (gefitinib), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 1 of them publish a price we can compare per daily dose

Gefitinib · ATC L01XE02

2 / 19 countries

  • Ireland
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Sorafenibum
Manufacturer
Sandoz GmbH
Country
Poland (PL)
ATC code
L01XE02
ATC class
Gefitinib
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    07613421049348

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

414 interactions on record for gefitinib.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Gefitinib · interactions on record

414 records

  • 11 severe
  • 193 moderate
  • 5 minor
  • 205 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Gefitinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All gefitinib products

Authorised across Europe · EMA

The same active substance is authorised in 29 EEA countries. Names it is sold under:

  • Austria · Sorafenib, Sorafenib Bluefish
  • Belgium · Sorafenib Eg, Sorafénib Eg
  • Bulgaria · Сорафениб Зентива, Сорафениб Тева
  • Cyprus · Rexanib
  • Czechia · Sorafenib Pharmagen, Sorafenib Sandoz
  • Germany · Sorafeb, Sorafenib Abz
  • Denmark · Sorafenib "sandoz", Sorafenib Stada
  • Estonia · Sorafenib Sandoz, Sorafenib Teva
  • Spain · Sorafenib Dr. Reddys, Sorafenib Eugia
  • Finland · Sorafenib Sandoz, Sorafenib Stada
  • France · Sorafenib Arrow, Sorafenib Biogaran
  • United Kingdom (Northern Ireland) · Sorafenib Sandoz, Sorafenib Teva
  • Greece · Revamox, Sorafenib Bioars
  • Croatia · Slam 200 Mg Tablete, Sorafenib Alpha-Medical
  • Hungary · Fenesa, Renixola
  • Iceland · Nexavar, Sorafenib
  • Italy · Sorafenib Eg, Sorafenib Medac
  • Liechtenstein · Nexavar, Sorafenib Accord
  • Lithuania · Sorafenib Sandoz, Sorafenib Teva
  • Luxembourg · Sorafenib Eg, Sorafenib Eurogenerics
  • Latvia · Sorafenib Lv System, Sorafenib Sandoz
  • Malta · Revamox, Sorafenib Pharos
  • Netherlands · Fenesa, Sorafeb
  • Norway · Nexavar, Sorafenib Accord
  • Portugal · Sorafenib, Sorafenib Eugia
  • Romania · Sorafenib Dr. Reddy's, Sorafenib Sandoz
  • Sweden · Sorafenib Bluefish, Sorafenib Sandoz
  • Slovenia · Sorafenib Sandoz, Sorafenib Teva
  • Slovakia · Sorafenib, Sorafenib Pharmagen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/1090a5c0-9fa9-46d9-b411-c4b797b38e0c
GET /v1/drugs/1090a5c0-9fa9-46d9-b411-c4b797b38e0c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "07613421049348 ¦ Rpz ¦ 141431\n56 tabl.",
  "substance": "Sorafenibi Tosilas 548 mg",
  "common_name": "Sorafenibum",
  "pl_product_id": "100435166",
  "pozwolenie_nr": "26558",
  "auth_procedure": "DCP",
  "authorisation_validity": "2024-10-10"
}

See everything about gefitinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.